The Potential Role of Lysosomal Sequestration in Sunitinib Resistance of Renal Cell Cancer
Renal cell carcinoma (RCC) is a highly vascularized tumor type, which is often associated with inactivated mutations in the von Hippel-Lindau gene that drives proangiogenic signaling pathways. As such, new therapies for the treatment of RCC have largely been focused on blocking angiogenesis. Sun...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Codon Publications
2016-01-01
|
Series: | Journal of Kidney Cancer and VHL |
Subjects: | |
Online Access: | https://jkcvhl.com/index.php/jkcvhl/article/view/44 |
id |
doaj-449c7c4543cd476bb0338d0f89ea5440 |
---|---|
record_format |
Article |
spelling |
doaj-449c7c4543cd476bb0338d0f89ea54402020-11-25T03:54:33ZengCodon PublicationsJournal of Kidney Cancer and VHL2203-58262016-01-012410.15586/jkcvhl.2015.4434The Potential Role of Lysosomal Sequestration in Sunitinib Resistance of Renal Cell CancerKaamar Azijli0Kristy J GotinkHenk M.W Verheul1Department of Medical Oncology, VU University Medical Center, AmsterdamDepartment of Medical Oncology, VU University Medical Center, Amsterdam Renal cell carcinoma (RCC) is a highly vascularized tumor type, which is often associated with inactivated mutations in the von Hippel-Lindau gene that drives proangiogenic signaling pathways. As such, new therapies for the treatment of RCC have largely been focused on blocking angiogenesis. Sunitinib, an antiangiogenic tyrosine kinase inhibitor, is the most frequently used first-line drug for the treatment of RCC. Although treatment with sunitinib improves patient outcome considerably, acquired resistance will emerge in all cases. The molecular mechanisms of resistance to sunitinib are poorly understood, but in the past decade, several of these have been proposed. Lysosomal sequestration of sunitinib was reported as a potential resistance mechanism to sunitinib. In this review, the underlying molecular mechanisms of lysosomal sunitinib sequestration and the potential strategies to overcome this resistance are discussed to be able to further improve the treatment of RCC. https://jkcvhl.com/index.php/jkcvhl/article/view/44Drug resistanceKidney cancerLysosomesLysosomal sequestrationRenal cell cancerSunitinib resistance |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Kaamar Azijli Kristy J Gotink Henk M.W Verheul |
spellingShingle |
Kaamar Azijli Kristy J Gotink Henk M.W Verheul The Potential Role of Lysosomal Sequestration in Sunitinib Resistance of Renal Cell Cancer Journal of Kidney Cancer and VHL Drug resistance Kidney cancer Lysosomes Lysosomal sequestration Renal cell cancer Sunitinib resistance |
author_facet |
Kaamar Azijli Kristy J Gotink Henk M.W Verheul |
author_sort |
Kaamar Azijli |
title |
The Potential Role of Lysosomal Sequestration in Sunitinib Resistance of Renal Cell Cancer |
title_short |
The Potential Role of Lysosomal Sequestration in Sunitinib Resistance of Renal Cell Cancer |
title_full |
The Potential Role of Lysosomal Sequestration in Sunitinib Resistance of Renal Cell Cancer |
title_fullStr |
The Potential Role of Lysosomal Sequestration in Sunitinib Resistance of Renal Cell Cancer |
title_full_unstemmed |
The Potential Role of Lysosomal Sequestration in Sunitinib Resistance of Renal Cell Cancer |
title_sort |
potential role of lysosomal sequestration in sunitinib resistance of renal cell cancer |
publisher |
Codon Publications |
series |
Journal of Kidney Cancer and VHL |
issn |
2203-5826 |
publishDate |
2016-01-01 |
description |
Renal cell carcinoma (RCC) is a highly vascularized tumor type, which is often associated with inactivated mutations in the von Hippel-Lindau gene that drives proangiogenic signaling pathways. As such, new therapies for the treatment of RCC have largely been focused on blocking angiogenesis. Sunitinib, an antiangiogenic tyrosine kinase inhibitor, is the most frequently used first-line drug for the treatment of RCC. Although treatment with sunitinib improves patient outcome considerably, acquired resistance will emerge in all cases. The molecular mechanisms of resistance to sunitinib are poorly understood, but in the past decade, several of these have been proposed. Lysosomal sequestration of sunitinib was reported as a potential resistance mechanism to sunitinib. In this review, the underlying molecular mechanisms of lysosomal sunitinib sequestration and the potential strategies to overcome this resistance are discussed to be able to further improve the treatment of RCC.
|
topic |
Drug resistance Kidney cancer Lysosomes Lysosomal sequestration Renal cell cancer Sunitinib resistance |
url |
https://jkcvhl.com/index.php/jkcvhl/article/view/44 |
work_keys_str_mv |
AT kaamarazijli thepotentialroleoflysosomalsequestrationinsunitinibresistanceofrenalcellcancer AT kristyjgotink thepotentialroleoflysosomalsequestrationinsunitinibresistanceofrenalcellcancer AT henkmwverheul thepotentialroleoflysosomalsequestrationinsunitinibresistanceofrenalcellcancer AT kaamarazijli potentialroleoflysosomalsequestrationinsunitinibresistanceofrenalcellcancer AT kristyjgotink potentialroleoflysosomalsequestrationinsunitinibresistanceofrenalcellcancer AT henkmwverheul potentialroleoflysosomalsequestrationinsunitinibresistanceofrenalcellcancer |
_version_ |
1724473148299018240 |